Medpace Holdings, Inc. (NASDAQ:MEDP) Receives $595.20 Average Price Target from Analysts

Medpace Holdings, Inc. (NASDAQ:MEDP) has earned an average recommendation of “Hold” from the twelve research firms that are presently covering the stock, Marketbeat reports. Nine analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $595.20.

A number of equities analysts recently commented on the company. Mizuho lifted their price objective on Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Weiss Ratings upgraded Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 12th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $535.00 target price on shares of Medpace in a research note on Thursday, July 23rd. Jefferies Financial Group lowered Medpace from a “buy” rating to a “hold” rating and lifted their price target for the stock from $490.00 to $515.00 in a report on Tuesday, July 7th. Finally, Truist Financial upped their price objective on shares of Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a report on Friday, July 24th.

Medpace Stock Performance

Shares of NASDAQ MEDP opened at $591.29 on Friday. The stock has a market cap of $16.50 billion, a PE ratio of 34.66, a P/E/G ratio of 2.64 and a beta of 1.15. Medpace has a 12-month low of $373.00 and a 12-month high of $677.90. The company has a 50-day moving average of $574.67 and a 200 day moving average of $500.02.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The business had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business’s revenue was up 17.2% on a year-over-year basis. During the same period last year, the company posted $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, sell-side analysts forecast that Medpace will post 17.54 EPS for the current fiscal year.

Insider Activity

In other news, Director Brian T. Carley sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $608.63, for a total transaction of $3,043,150.00. Following the completion of the sale, the director owned 27,825 shares in the company, valued at $16,935,129.75. This trade represents a 15.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Susan E. Burwig sold 7,500 shares of Medpace stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $600.00, for a total transaction of $4,500,000.00. Following the sale, the vice president directly owned 62,984 shares in the company, valued at approximately $37,790,400. The trade was a 10.64% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 134,471 shares of company stock valued at $82,151,311. Company insiders own 20.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in MEDP. American Capital Management Inc. purchased a new stake in Medpace during the 2nd quarter worth about $111,329,000. California State Teachers Retirement System increased its holdings in shares of Medpace by 22.1% in the 1st quarter. California State Teachers Retirement System now owns 26,042 shares of the company’s stock valued at $12,505,000 after acquiring an additional 4,719 shares during the last quarter. Focus Partners Advisor Solutions LLC purchased a new position in shares of Medpace in the 2nd quarter valued at about $1,685,000. BlackRock Inc. acquired a new stake in shares of Medpace during the 2nd quarter worth about $1,323,047,000. Finally, Rice Hall James & Associates LLC acquired a new stake in shares of Medpace during the 2nd quarter worth about $28,659,000. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.